Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: N-terminal fragment of B-type natriuretic peptide (NT-proBNP), a marker of cardiac safety during antipsychotic treatment. | Annals of General Psychiatry BioMed Central Primary research Open Access N-terminal fragment of B-type natriuretic peptide NT-proBNP a marker of cardiac safety during antipsychotic treatment Stefan Kropp 1 Argyro Tountopoulou1 Udo Schneider2 and Ralf Lichtinghagen3 Address Department of Clinical Psychiatry and Psychotherapy Hannover Medical School 30623 Hannover Germany 2Department of Psychiatry and Psychotherapy Lubbecke Medical Hospital Virchowstr. 65 32312 Lubbecke Germany and 3Department of Clinical Chemistry Hannover Medical School 30623 Hannover Germany Email Stefan Kropp - kropp.stefan@mh-hannover.de Argyro Tountopoulou - argyro@vip.gr Udo Schneider - udo.schneider@krankenhaus-luebbecke.de Ralf Lichtinghagen - lichtinghagen.ralf@mh-hannover.de Corresponding author Published 09 May 2005 Received 06 March 2004 Annals of General Psychiatry 2005 4 10 doi 10.1186 1744-859X-4-10 Accepted 09 May 2005 This article is available from http www.annals-general-psychiatry.cOm content 4 1 10 2005 Kropp et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.Org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The potential cardiotoxicity of antipsychotic drugs is well known. The N-terminal fragment of B-type natriuretic peptide NT-proBNP is considered to be a possible biomarker in clinical practice for the diagnosis and prognosis in patients with suspected heart failure. This pilot evaluation tests the influence of antipsychotic drugs on NT-proBNP concentration in view of the hypothesis that NT-proBNP could be used as marker for the tolerability and safety of antipsychotic medications. Methods On a routine basis patient s blood samples were examined for NT-proBNP on days 0 7 and 21 after initiation of a new antipsychotic monotherapy. All plasma samples were analysed
